A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 303 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery November 30, 2018 FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer... April 19, 2021 Today is Random Acts of Kindness Day February 17, 2021 Cancer in My Community: The Roadblocks to Receiving Cancer Care in... September 23, 2021 Load more HOT NEWS Curbing Production of Immune Checkpoint Protein Slows Liver Cancer in Mice Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in... EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) A winding journey into the world of children’s and young people’s...
